Autonomous AI post-training reached frontier scale for the first time: NVIDIA researchers published a paper showing an AI ...

OpenAI and Broadcom unveiled Jalapeño, a custom AI inference chip designed in nine months. Early tests show 50% cost savings over standard GPUs, with deployment planned for late 2026.

Coinbase co-founder and CEO Brian Armstrong joins Yahoo Finance Executive Editor Brian Sozzi to explain how they're building ...

The super app is the oldest trick in the technology playbook. OpenAI is staking its IPO valuation on AI to make it work.

Recently, the concept of so-called covenants has received renewed attention as Bitcoin development and protocol discussions underwent a renaissance. Covenants could enable and facilitate a wide range ...

A buffer overflow happens when a program writes more data into a memory buffer than the buffer can hold. The extra bytes land in adjacent memory, corrupting whatever was there. If an attacker controls ...

Most coverage treats “the Palantir Mafia” as a cute analogy — a nod to the PayPal Mafia that gave us Tesla, LinkedIn, YouTube and Yelp. That framing undersells it. The Palantir Mafia is not analogous ...

Ongoing research into AI agent framework security identified an exploit chain in AutoGen Studio (AutoGen’s open-source prototyping user interface) that allows untrusted web content rendered by a ...

Vibe-coding is revolutionizing software development and making it easier than ever to build fully functional websites and apps from scratch. Coined in 2025 by AI researcher […] ...

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...